MRKR
Marker Therapeutics, Inc.
$1.51
-0.07 (-4.43%)
At close · Jul 10
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$25.18M
Shares
16,673,127
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.55M
-46.2%
FY2025
Net Income
-$12.16M
-13.3%
FY2025
Operating Margin
-363.45%
-194.8pp
FY2025
Diluted EPS
-$0.79
+33.6%
FY2025
Operating Cash Flow
-$12.01M
-10.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.95M | $3.55M | $6.59M | $3.31M | $9.01M | $0 | $466.79K | $213.19K | $205.99K | — | — | — | — | — | — | — | |
| $11.51M | $11.8M | $13.47M | $10.42M | $26.14M | $27.79M | $18.88M | $12.76M | $7.95M | $5.25M | $3.8M | $1.71M | $189K | $7.6M | $6.97M | $5.91M | |
| $4.05M | $4.18M | $4.24M | $7.48M | $12.82M | $12.92M | $10.47M | $9.98M | $24.38M | $6.41M | $4.69M | $4.45M | $3.18M | $4.51M | $3.93M | $2.92M | |
| — | — | — | — | $2.79M | $2.15M | $485.64K | $105.12K | — | — | — | — | — | — | — | — | |
| $15.55M | $16.44M | $17.71M | $17.89M | $38.96M | $40.72M | $29.35M | $22.74M | $148.38M | $11.66M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $35.27M | |
| -$12.01M | -$12.89M | -$11.12M | -$14.58M | -$29.95M | -$39.48M | -$28.89M | -$22.53M | -$148.17M | -$11.66M | -$8.49M | -$6.16M | -$3.37M | — | — | -$35.27M | |
| — | -363.45% | -168.69% | -440.37% | -332.23% | — | -6188.25% | -10567.28% | -71930.07% | — | — | — | — | — | — | — | |
| — | — | — | — | -$27.16M | -$37.33M | -$28.4M | -$22.42M | — | — | — | — | — | — | — | — | |
| $564.61K | $594.21K | $437.01K | $539.16K | $248.06K | $5700 | $148.74K | $1.08M | $253.72K | — | — | — | — | — | $33.34K | $33.34K | |
| — | -$12.18M | -$10.68M | -$14.04M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$15.16K | $49.95K | $3675 | — | — | — | — | $0 | $0 | $0 | $0 | — | — | — | — | |
| -$10.9M | -$12.16M | -$10.73M | -$8.24M | -$29.93M | -$41.88M | -$28.71M | -$21.43M | -$147.96M | -$10.98M | -$2.46M | -$34.07M | -$30.88M | — | -$49.58M | -$43.72M | |
| — | -342.96% | -162.82% | -248.76% | -332.06% | — | -6149.74% | -10050.92% | -71826.32% | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$30.82M | — | — | — | |
| USD/shares | — | -$0.79 | -$1.19 | -$0.94 | -$3.58 | -$5.50 | — | — | — | -$11.60 | -$3.60 | — | — | — | — | — |
| USD/shares | — | -$0.79 | -$1.19 | -$0.94 | -$3.58 | -$5.50 | — | — | — | -$11.60 | -$7.20 | — | — | — | — | — |
| shares | — | 15.31M | 8.98M | 8.81M | 8.35M | 7.65M | 4.7M | 4.56M | 1.91M | 945.35K | 688.99K | 4.39M | 1.55M | — | — | — |
| shares | — | 15.31M | 8.98M | 8.81M | 8.35M | 7.65M | 4.7M | 4.56M | 1.91M | 945.35K | 742.1K | 4.39M | 1.55M | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2019: $453.91K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia | $900,014 | $4,411,149 | — | — | — | — | — |
| National Institutes Of Health Small Business Innovation Research For Lymphoma Grant | $665,000 | $665,000 | — | — | — | — | — |
| Cprit Pancreatic Grant | $573,994 | — | — | — | — | — | — |
| National Institutes Of Health Small Business Innovation Research | $472,208 | $982,182 | $200,000 | — | — | — | — |
| National Institutes Of Health Small Business Innovation Research For Pancreatic Cancer | $425,670 | $7,177 | — | — | — | — | — |
| National Institutes Of Health National Cancer Institute Grant | $391,305 | $5,822 | — | — | — | — | — |
| Fda Grant | $118,478 | $519,750 | $400,000 | $100,000 | — | — | — |
| Cprit Grant | — | $200,000 | $2,700,000 | $3,400,000 | — | — | — |
| Grant | — | $6,591,080 | — | $3,513,544 | $1,241,710 | $466,785 | $213,194 |
| Service | — | — | — | $5,500,000 | — | — | — |